Infection prevention in patients receiving CAR T-cells

Joshua Hill, MD, Fred Hutchinson Cancer Research Center, Seattle, WA, explores the strategies and recommendations for infection prophylaxis and monitoring in CAR-T patients. Dr Hill discusses antibacterial, antiviral, and antifungal prophylaxis. IV IG is reserved for patients with very low IgG levels and recurrent or severe bacterial infections primarily. Additionally, vaccination strategies post CAR T-cell therapy are debated, including COVID-19 vaccination. This interview took place during the 3rd European CAR T-cell Meeting.